UT-MD Anderson Cancer Center: Lung Cancer Outcomes Significantly Improved With Immunotherapy-Based Treatment Given Before and After Surgery
October 24, 2023
October 24, 2023
HOUSTON, Texas, Oct. 24 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Phase III trial finds 32% lower chance of disease recurrence, progression or death with immunotherapy plus chemotherapy versus chemotherapy alone
* * *
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic c . . .
* * *
Phase III trial finds 32% lower chance of disease recurrence, progression or death with immunotherapy plus chemotherapy versus chemotherapy alone
* * *
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic c . . .